These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 33912731)
1. A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay. Lei RY; Carter DL; Antell AG; Nowels MA; Tole SP; Bennett JP; Turner M; Baehner FL; Leonard CE Adv Radiat Oncol; 2021; 6(2):100607. PubMed ID: 33912731 [TBL] [Abstract][Full Text] [Related]
2. Ipsilateral tumor recurrence risk in women with ductal carcinoma in situ: application of the Van Nuys Prognostic Index and the Memorial Sloan Kettering Cancer Center nomogram. Hashiba KA; Bahl M Breast Cancer Res Treat; 2023 Nov; 202(1):185-190. PubMed ID: 37518825 [TBL] [Abstract][Full Text] [Related]
3. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039 [TBL] [Abstract][Full Text] [Related]
4. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. Solin LJ; Gray R; Hughes LL; Wood WC; Lowen MA; Badve SS; Baehner FL; Ingle JN; Perez EA; Recht A; Sparano JA; Davidson NE J Clin Oncol; 2015 Nov; 33(33):3938-44. PubMed ID: 26371148 [TBL] [Abstract][Full Text] [Related]
5. Local relapse after breast-conserving therapy for ductal carcinoma in situ: a European single-center experience and external validation of the Memorial Sloan-Kettering Cancer Center DCIS nomogram. Sweldens C; Peeters S; van Limbergen E; Janssen H; Laenen A; Patil S; Van Zee KJ; Weltens C Cancer J; 2014; 20(1):1-7. PubMed ID: 24445756 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery. Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458 [TBL] [Abstract][Full Text] [Related]
7. Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score. Van Zee KJ; Zabor EC; Di Donato R; Harmon B; Fox J; Morrow M; Cody HS; Fineberg SA Ann Surg Oncol; 2019 Oct; 26(10):3282-3288. PubMed ID: 31342373 [TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ. Raldow AC; Sher D; Chen AB; Recht A; Punglia RS J Clin Oncol; 2016 Nov; 34(33):3963-3968. PubMed ID: 27621393 [TBL] [Abstract][Full Text] [Related]
9. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650 [TBL] [Abstract][Full Text] [Related]
10. Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study. Wright JL; Gray R; Rahbar H; Comstock CE; Tjoe JA; Badve S; Recht A; Sparano JA; Davidson NE; Wolff AC NPJ Breast Cancer; 2024 Feb; 10(1):16. PubMed ID: 38396024 [TBL] [Abstract][Full Text] [Related]
11. Validation of a nomogram in the prediction of local recurrence risks after conserving surgery for Asian women with ductal carcinoma in situ of the breast. Wang F; Li H; Tan PH; Chua ET; Yeo RM; Lim FL; Kim SW; Tan DY; Wong FY Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):684-91. PubMed ID: 25194727 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. Yi M; Meric-Bernstam F; Kuerer HM; Mittendorf EA; Bedrosian I; Lucci A; Hwang RF; Crow JR; Luo S; Hunt KK J Clin Oncol; 2012 Feb; 30(6):600-7. PubMed ID: 22253459 [TBL] [Abstract][Full Text] [Related]
13. Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study. Collins LC; Achacoso N; Haque R; Nekhlyudov L; Quesenberry CP; Schnitt SJ; Habel LA; Fletcher SW Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S502-8. PubMed ID: 26059650 [TBL] [Abstract][Full Text] [Related]
14. DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS. Rakovitch E; Parpia S; Koch A; Grimard L; Soliman H; Stevens C; Perera F; Kong I; Senthelal S; Anthes M; Wiebe E; Cao J; Goldberg M; Smith S; Spadafora L; Whelan TJ Breast Cancer Res Treat; 2021 Jul; 188(1):133-139. PubMed ID: 33830392 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Score-Based Stratification Analysis Reveals Universal Benefits of Radiotherapy on Lowering the Risk of Ipsilateral Breast Event for Ductal Carcinoma In Situ Patients with Different Risk Levels. Yang L; Lu D; Lai Y; Shen M; Yu Q; Lei T; Pu T; Bu H Ann Surg Oncol; 2021 Feb; 28(2):975-984. PubMed ID: 32794031 [TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. Manders JB; Kuerer HM; Smith BD; McCluskey C; Farrar WB; Frazier TG; Li L; Leonard CE; Carter DL; Chawla S; Medeiros LE; Guenther JM; Castellini LE; Buchholz DJ; Mamounas EP; Wapnir IL; Horst KC; Chagpar A; Evans SB; Riker AI; Vali FS; Solin LJ; Jablon L; Recht A; Sharma R; Lu R; Sing AP; Hwang ES; White J; Ann Surg Oncol; 2017 Mar; 24(3):660-668. PubMed ID: 27704370 [TBL] [Abstract][Full Text] [Related]
17. Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram. Oses G; Mension E; Pumarola C; Castillo H; Francesc L; Torras I; Cebrecos I; Caparrós X; Ganau S; Ubeda B; Bargallo X; González B; Sanfeliu E; Vidal-Sicart S; Moreno R; Muñoz M; Santamaría G; Mollà M Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190320 [TBL] [Abstract][Full Text] [Related]
18. Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions. Lin CY; Mooney K; Choy W; Yang SR; Barry-Holson K; Horst K; Wapnir I; Allison K Mod Pathol; 2018 Apr; 31(4):562-568. PubMed ID: 29243740 [TBL] [Abstract][Full Text] [Related]
19. Postoperative radiotherapy after DCIS: Useful for whom? Karlsson P Breast; 2017 Aug; 34 Suppl 1():S43-S46. PubMed ID: 28663003 [TBL] [Abstract][Full Text] [Related]
20. Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial. Thorat MA; Levey PM; Jones JL; Pinder SE; Bundred NJ; Fentiman IS; Cuzick J Clin Cancer Res; 2021 Oct; 27(19):5317-5324. PubMed ID: 34380636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]